Akèy › Limfòm Non-Hodgkin › Tennessee › Nashville
Etid klinik pou Limfòm Non-Hodgkin nan Nashville, TN
21 etid pou Limfòm Non-Hodgkin ap chèche patisipan nan sit nan ak bò kote Nashville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
- Tennessee Oncology, Pllc Nashville, Nashville
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Ap rekriteFaz 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Ap rekriteFaz 1/2
- SCRI Oncology Partners ( Site 0100), Nashville
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Ap rekriteFaz 2
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- SCRI Oncology Partners, Nashville
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Ap rekriteFaz 1
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Ap rekriteFaz 1
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Ap rekriteFaz 2
- Research Site, Nashville
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Ap rekriteFaz 2
- Tennessee Oncology, Nashville
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Ap rekriteFaz 1
- SCRI Oncology Partners, Nashville
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1/2
- Research Site, Franklin · 17 mi lwen
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- Vanderbilt University Medical Center, Nashville
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Ap rekriteFaz 3
- Sarah Cannon Research Institute SCRI, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
- TriStar BMT, Nashville
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Ap rekriteFaz 3
- SCRI Oncology Partners, Nashville
DALY II USA/ MB-CART2019.1 for DLBCL
Ap rekriteFaz 2
- SCRI Oncology Partners, Nashville
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- Vanderbilt University, Nashville
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Ap rekriteFaz 4
- Tennessee Oncology, Nashville
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Ap rekriteFaz 4
- Tennessee Oncology, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Nashville
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Ap rekriteFaz 1/2
- SCRI Oncology Partners, Nashville
Etid Limfòm Non-Hodgkin nan lòt vil
- New York City, NY31 etid
- Houston, TX31 etid
- Boston, MA26 etid
- Philadelphia, PA20 etid
- Baldwin Park, CA19 etid
- Washington, DC18 etid
- Chicago, IL18 etid
- Milwaukee, WI18 etid
- Atlanta, GA18 etid
- Columbus, OH18 etid
- Dallas, TX17 etid
- Seattle, WA16 etid
Lòt etid nan Nashville
- Kansè Poumon ki pa ti selil97 etid
- Kansè nan tete81 etid
- Kansè Metastatik70 etid
- Kansè kolorektal69 etid
- Kansè (tout kalite)65 etid
- Kansè ovè49 etid
- Kansè pwostat43 etid
- Kansè poumon40 etid
- Karsinòm selil skuamèz tèt ak kou39 etid
- Kansè pankreyas39 etid
- Kansè Endomèt38 etid
- Melanom33 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.